67. 多発性嚢胞腎
[臨床試験数:186,薬物数:196(DrugBank:47),標的遺伝子数:35,標的パスウェイ数:146

Searched query = "Polycystic kidney disease", "PKD", "PCKD", "Polycystic kidney", "ADPKD", "ARPKD"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
9 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-004651-20-GB
(EUCTR)
13/02/202007/08/2019A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Polycystic Kidney DiseaseA Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease - FALCON Autosomal dominant polycystic kidney disease
MedDRA version: 20.0;Level: LLT;Classification code 10036046;Term: Polycystic kidney, autosomal dominant;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Bardoxolone methyl 5 mg
Product Code: RTA 402
INN or Proposed INN: Bardoxolone Methyl
Other descriptive name: BARDOXOLONE METHYL
Product Name: Bardoxolone methyl 10 mg
Product Code: RTA 402
INN or Proposed INN: Bardoxolone Methyl
Other descriptive name: BARDOXOLONE METHYL
Product Name: Bardoxolone methyl 20 mg
Product Code: RTA 402
INN or Proposed INN: Bardoxolone Methyl
Other descriptive name: BARDOXOLONE METHYL
Product Name: Bardoxolone methyl 15 mg
Product Code: RTA 402
INN or Proposed INN: Bardoxolone Methyl
Other descriptive name: BARDOXOLONE METHYL
Reata Pharmaceuticals, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
300Phase 3United States;France;Czech Republic;Spain;Belgium;Australia;Germany;Italy;United Kingdom
2EUCTR2018-004651-20-DE
(EUCTR)
20/01/202007/08/2019A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Polycystic Kidney DiseaseA Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease - FALCON Autosomal dominant polycystic kidney disease
MedDRA version: 20.0;Level: LLT;Classification code 10036046;Term: Polycystic kidney, autosomal dominant;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Bardoxolone methyl 5 mg
Product Code: RTA 402
INN or Proposed INN: Bardoxolone Methyl
Other descriptive name: BARDOXOLONE METHYL
Product Name: Bardoxolone methyl 10 mg
Product Code: RTA 402
INN or Proposed INN: Bardoxolone Methyl
Other descriptive name: BARDOXOLONE METHYL
Product Name: Bardoxolone methyl 20 mg
Product Code: RTA 402
INN or Proposed INN: Bardoxolone Methyl
Other descriptive name: BARDOXOLONE METHYL
Product Name: Bardoxolone methyl 15 mg
Product Code: RTA 402
INN or Proposed INN: Bardoxolone Methyl
Other descriptive name: BARDOXOLONE METHYL
Reata Pharmaceuticals, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
300Phase 3United States;France;Czechia;Czech Republic;Spain;Belgium;Australia;Germany;United Kingdom;Italy
3EUCTR2018-004651-20-CZ
(EUCTR)
12/12/201923/08/2019A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Polycystic Kidney DiseaseA Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease - FALCON Autosomal dominant polycystic kidney disease
MedDRA version: 20.0;Level: LLT;Classification code 10036046;Term: Polycystic kidney, autosomal dominant;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Bardoxolone methyl 5 mg
Product Code: RTA 402
INN or Proposed INN: Bardoxolone Methyl
Other descriptive name: BARDOXOLONE METHYL
Product Name: Bardoxolone methyl 10 mg
Product Code: RTA 402
INN or Proposed INN: Bardoxolone Methyl
Other descriptive name: BARDOXOLONE METHYL
Product Name: Bardoxolone methyl 20 mg
Product Code: RTA 402
INN or Proposed INN: Bardoxolone Methyl
Other descriptive name: BARDOXOLONE METHYL
Product Name: Bardoxolone methyl 15 mg
Product Code: RTA 402
INN or Proposed INN: Bardoxolone Methyl
Other descriptive name: BARDOXOLONE METHYL
Reata Pharmaceuticals, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
300Phase 3United States;France;Czechia;Czech Republic;Spain;Belgium;Australia;Germany;United Kingdom;Italy
4EUCTR2018-004651-20-ES
(EUCTR)
19/11/201904/09/2019A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Polycystic Kidney DiseaseA Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease - FALCON Autosomal dominant polycystic kidney disease
MedDRA version: 20.0;Level: LLT;Classification code 10036046;Term: Polycystic kidney, autosomal dominant;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Reata Pharmaceuticals, Inc.NULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
300 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noFrance;United States;Czech Republic;Belgium;Spain;Australia;Germany;Italy;United Kingdom
5EUCTR2018-004651-20-BE
(EUCTR)
14/10/201929/08/2019 A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Polycystic Kidney DiseaseA Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease - FALCON Autosomal dominant polycystic kidney disease
MedDRA version: 20.0;Level: LLT;Classification code 10036046;Term: Polycystic kidney, autosomal dominant;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Reata Pharmaceuticals, Inc.NULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
300 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noFrance;United States;Czech Republic;Spain;Belgium;Australia;Germany;Italy;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT03918447
(ClinicalTrials.gov)
May 29, 201912/4/2019A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCONA Phase 3 Trial of Bardoxolone Methyl in Patients With Autosomal Dominant Polycystic Kidney DiseaseAutosomal Dominant Polycystic Kidney;ADPKDDrug: Bardoxolone methyl oral capsule;Drug: Placebo oral capsuleReata Pharmaceuticals, Inc.NULLRecruiting18 Years70 YearsAll300Phase 3United States;Australia;Belgium;Czechia;France;Germany;Italy;Japan;Spain;United Kingdom
7NCT03749447
(ClinicalTrials.gov)
March 8, 201919/11/2018An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)An Extended Access Program to Assess Long Term Safety of Bardoxolone Methyl in Patients With Chronic Kidney DiseaseChronic Kidney Diseases;Alport Syndrome;Autosomal Dominant Polycystic KidneyDrug: Bardoxolone methylReata Pharmaceuticals, Inc.NULLRecruiting12 YearsN/AAll480Phase 3United States;Australia;Japan;Puerto Rico
8JPRN-UMIN000039943
2019/03/0825/03/2020An Extended Access Program to Assess Long Term Safety of Bardoxolone Methyl in Patients with Chronic Kidney DiseaseAn Extended Access Program to Assess Long Term Safety of Bardoxolone Methyl in Patients with Chronic Kidney Disease - A Trial of Bardoxolone Methyl in Patients with Chronic Kidney Disease - EAGLE Chronic Kidney DiseaseAlport SyndromeAutosomal Dominant Polycystic KidneyBardoxolone methylReata Pharmaceuticals, Inc.Kyowa Kirin Co., Ltd.RecruitingNot applicableNot applicableMale and Female180Phase 3Japan,North America,Australia,Europe
9NCT03366337
(ClinicalTrials.gov)
December 26, 20174/12/2017A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIXA Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney DiseasesIgA Nephropathy;CKD Associated With Type 1 Diabetes;Focal Segmental Glomerulosclerosis;Autosomal Dominant Polycystic KidneyDrug: Bardoxolone methyl capsulesReata Pharmaceuticals, Inc.NULLCompleted18 Years65 YearsAll103Phase 2United States